Skip to the reading
OrlandoPeptide primer

A guide for your care questions

Orlando care, in plain words

Is peptide care allowed?

Ask which medicine you would receive and whether a pharmacy would make it to order. The rules depend on those details.

The finished product matters.

As of September 26, 2026, US rules differ for approved medicines, medicines made to order and other products without approval.

Federal law does not give “peptide therapy” one legal meaning, as of that date. That phrase alone cannot tell you whether a particular treatment is allowed.

Ask for the medicine’s name and the health problem it would address.

Compounding can meet a need, but has conditions.

FDA guidance, as of September 26, 2026, describes compounding as a possible way to meet a need that an approved medicine cannot meet.

A medicine made to order still lacks FDA approval, even when making it is lawful.

The FDA does not check its safety, quality or benefit before sale.

Ask what need a ready-made medicine would leave unmet. Ask for the pharmacy name and that reason in writing.

Why are copies of ready-made medicines limited?

Federal law, as of September 26, 2026, restricts making near-copies of available ready-made medicines repeatedly or in unusually large amounts.

The person writing the prescription may record how a change to the medicine would make a real medical difference for that patient. Paying less does not count.

Ask what would change, such as leaving out a dye you cannot have, and why that change matters for you.

FDA’s national shortage list does not include injections of semaglutide or tirzepatide, as of September 26, 2026.

An injection with the same medicine ingredient and a similar strength may still count as a copy when a vitamin is added.

Ask about products labelled “for research.”

FDA warns against unapproved products sold under “research” labels for human use, as of September 26, 2026.

BPC-157 and ipamorelin have no approved US product as of that date.

Retatrutide is being studied as a medicine; it has no FDA-approved product as of September 26, 2026.

Federal law bars compounding with retatrutide or cagrilintide, according to FDA’s explanation as of September 26, 2026.

When an offer names any of these products, ask whether the exact product has FDA approval and which law permits supplying it.

Ask for an answer about this product, now.

Ask: “What rule allows this medicine to be made or supplied for me?” Get the explanation and pharmacy name in writing. Keep them with the price quote.

Read a little further